Biotop-report 2014

5

BioTOPics 47 | 6. Juni 2014 (3:02) 

BioTOP-Report

 Biotechnology 

Key milestones achieved

MOLOGEN completed a successful fiscal year 2013 with three 

different product candidates in clinical development for the first 

time. The final evaluations for the completed clinical trials of  

MGN1703 and MGN1601 provided very positive data, and with 

MGN1404 (a product that combats malignant melanoma), the 

company launched the clinical development phase of  another 

product candidate within the framework of  a partnership, contrib-

uting to an expansion of  its pipeline. For its most advanced prod-

uct candidate, the cancer immunotherapy MGN1703, MOLOGEN 

was also able to present very positive clinical data from the final 

evaluation of  a phase II trial in colorectal cancer (IMPACT study) 

in 2013. For the most part, the preparations for a phase III pivotal 

study in this indication were completed in the course of  the last 

fiscal year.

Glycotope specializes in the glycosylation of  proteins. Glycotope 

has a broad portfolio of  drugs in clinical development, including 

the new cancer drugs, PankoMab-GEX™ and CetuGEX™, both 

in phase IIb trials. PankoMab-GEX™ is the first fully glycosylated 

and glyco-optimized human antibody for a novel tumor-specific 

carbohydrate-protein mixed epitope (TA-MUC1) abundantly pres-

ent in a larger set of  tumor indications, metastases and cancer 

stem cells. Additional Glycotope products include TrasGEX™, 

which has successfully completed its phase I/IIa trial and the im-

proved fertility hormone FSH-GEX™, which is expected to begin 

two phase III clinical trials in 2014.

Biopharmaceuticals company 

NOXXON Pharma is a pioneer in 

the development of  a new class of  proprietary therapeutic agents 

called “Spiegelmers,” which are chemically synthesized L-ste-

Dr. Matthias Schroff

CEO MOLOGEN AG

We are well aware that our company’s success is also due to 

the conditions that Berlin and the capital region offer. Wheth-

er research collaboration (FU Berlin) or clinical studies with 

Charité Universitätsmedizin and its departments – we benefit 

from the close scientific network. The availability of  qualified 

personell is also a key advantage, which surely ties into the 

high quality of  life in Berlin. Berlin is a city for conferences 

and conventions and many of  our sector associations have 

their headquarters here. This is another reason why Berlin is 

an excellent location for medical biotechnology. As a research 

company, we appreciate the fact that Berlin is one of  the 

world's leading regions and innovative locations in the field 

of  life sciences.

therapy field, opens a central European production facility in Berlin-Buch

 +++ 

ProBioGen upholds strong patent position in viral vaccine manufacturing field

NOVEMBER 13

Glycotopes Fully Human and Glycooptimized Recombinant FSH-GEX exhibits 

superior activity and excellent tolerability in phase II clinical trial for in vitro 

fertilization

 +++ 

The methylated SHOX2 biomarker from Epigenomics shows 

promising results for therapy-related monitoring of  lung cancer patients

 +++ 

SCIENION´s sciFLEXARRAYER receives product technology innovation award 

from Materials Science Society AVS

 +++ 

The NeuroPro Alliance, a joint ven-

ture between the Technical University of  Applied Sciences Wildau, nanoPET 

Pharma GmbH and AudioCure Pharma GmbH, receives research award.

DECEMBER 13

OMEICOS Therapeutics: new drug for atrial fibrillation in model systems tests 

positively

 +++ 

Contichrom

®

 systems from KNAUER receive Berlin-Branden-

burg Innovation Award

 +++ 

ProBioGen announces expansion of  commercial 

licenses with emergent biosolutions for AGE1.CR

®

 viral vaccine manufacturing 

production platform 

JANUARY 14

Improved diagnostics for sepsis-associated liver dysfunction with LiMAx test 

from Humedics GmbH

 +++ 

Epigenomics starts trading on US OTCQX mar-

ket

 +++ 

Cell Medica announces European Union orphan drug designation for 

Cytovir ADV

 +++ 

ward-winning Ostendum Lab-on-a-Chip nanodevices are pro-

duced with SCIENION's sciFLEXARRAYER SX

FEBRUARY 14

The Swedish-German company Amal Therapeutics SA has acquired investors 

for a seed financing round

 +++ 

mivenion GmbH receives FDA approval for 

Xiralite

®

 Fluorescence Imaging System X4 for microcirculation visualization

 +++ 

€15 million for Mologen

MARCH 14

Glycotope GmbH raises €55 million

 +++ 

FDA Advisory Committee Provides 

Recommendations for Epigenomics' Colorectal Cancer Screening Blood Test

APRIL 14

Alacris Theranostics GmbH announces partnership with Walldorfer SAP AG

 

+++ 

On May 14, Bayer HealthCare opened its first German CoLaborator in 

Berlin-Mitte on the company's premises

 +++ 

Bayer Pharma AG participates 

in the High-Tech Startup Fund II

 +++ 

International pharmaceutical company 

Takeda extends production facility in Oranienburg

---